Miglustat is an imino sugar derivative classified as an inhibitor of the enzyme glucosylceramide synthase, approved for the treatment of mild-to-moderate type I Gaucher disease in adult patients for whom… Read more







![Chemical structure of 1-((3aR,5R,6S,6aR)-6-Hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)ethane-1,2-diol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F253328-56-2-1-3aR5R6S6aR-6-Hydroxy-22-dimethyltetrahydrofuro23-d13dioxol-5-ylethane-12-diol.png&w=3840&q=75)
































Miglustat is an imino sugar derivative classified as an inhibitor of the enzyme glucosylceramide synthase, approved for the treatment of mild-to-moderate type I Gaucher disease in adult patients for whom enzyme replacement therapy is not a suitable option. This category features high-quality reference standards for Miglustat, including its pharmacopeial and non-pharmacopeial impurities, degradation products, and metabolites such as glucuronides. Laboratories utilize these compounds for comprehensive impurity profiling, method validation, and rigorous quality control in pharmaceutical development. Additionally, stable isotope labelled compounds are available to serve as precise internal standards for mass spectrometry-based analytical testing, facilitating the accurate quantification and identification of the drug and its related substances in complex biological or chemical matrices. These analytical tools are essential for maintaining regulatory compliance and ensuring the consistent quality of pharmaceutical products throughout the manufacturing lifecycle.